scholarly journals Depressive-anxious disorders in clinical picture of bronchial asthma combined with erosive-ulcerous affections of gastroduodenal zone

2004 ◽  
Vol 3 (4) ◽  
pp. 57-62
Author(s):  
Ye. A. Ustjuzhanina ◽  
G. M. Chernyavskaya ◽  
E. I. Beloborodova ◽  
N. A. Kornetov
Keyword(s):  
Bronchial Asthma ◽  
Clinical Picture ◽  
Older Age ◽  
Depression And Anxiety ◽  
Antidepressant Use ◽  
Gastroduodenal Zone

In the paper a popularity frequency and peculiarities of depressive-troubled disorder (DAD) course at patients with bronchial asthma (BA) have been estimated depending on the presence of associated erosive-ulcerous affections of gastroduodenal zone (EUA GDZ) and an impact of DAD on BA course has been studied. Depressive-anxious disorders have been revealed at 87 (78%) of 112 interrogated patients, most of them had the depression of medium degree that had required a therapy with the possible antidepressant use. Combined disorders in the form of depression and anxiety prevailed. It has been found that persons of the older age were subjected to the risk of DAD development. Patients with mixed pathology had more expressed DAD.

Depression and Anxiety in Patients Undergoing Diagnostic Investigations for Head and Neck Cancers

1986 ◽  
Vol 149 (4) ◽  
pp. 491-493 ◽  
Author(s):  
A. D. M. Davies ◽  
C. Davies ◽  
M. C. Delpo
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Clinical Picture ◽  
Depression And Anxiety ◽  
Head And Neck Oncology ◽  
Self Assessment ◽  
Diagnostic Biopsy ◽  
Oncology Unit ◽  
Assessment Scales ◽  
Diagnostic Investigations

Patients attending a regional head and neck Oncology Unit were assessed for depression and anxiety (using the Leeds self-assessment scales) before diagnostic biopsy investigations. At the time of the assessments, neither patients nor investigators knew the biopsy results. Patients whose biopsies subsequently proved positive (showing the presence of a tumour) had significantly higher depression scores than those whose biopsies were negative. Differences in mean anxiety scores did not differ between groups. It is suggested that depression is part of the clinical picture of head and neck cancer.

scholarly journals The serum eosinophil cationic protein concentration in patients with bronchial asthma and its correlation with severity and exacerbation of the disease

2003 ◽  
Vol 22 (3) ◽  
pp. 249-253
Author(s):  
Snezana Kovacevic ◽  
Mirjana Bogic ◽  
Aleksandra Peric-Popadic ◽  
Sanvila Raskovic ◽  
Zikica Jovicic ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Clinical Picture ◽  
Healthy Subjects ◽  
Protein Concentration ◽  
Geometric Mean ◽  
Eosinophil Cationic Protein ◽  
Cationic Protein ◽  
Asthmatic Patients ◽  
Severity Of Disease ◽  
Severity Of The Disease

Activated eosinophilic leukocyte in asthma secretes numerous mediators, among which is ECP as well. The object of our study was to measure the serum ECP concentrations in 46 asthmatic patients with exacerabating and stable asthma, and to correlate the serum ECP concentrations with severity and exacerbation of the disease. Geometric mean of ECP in serum (Gecp) in our group of patients was 7.5 mcg/l, while it was 3.05 mcg/l in the 15 healthy subjects (controls). Highly significant correlation of serum ECP concentrations with the activity of the disease (R=0.897) and the severity of clinical picture (R=0.79) was found. The patients with stable asthma had significant correlation of ECP and the severity of disease (R=0.6). The patients with exacerbating asthma have significantly higher serum ECP concentrations than the patients with stable asthma. Serum ECP concentrations in patients with exacerbating asthma correlate with the severity of the disease.

scholarly journals Changes in antidepressant use in Australia: A nationwide analysis prior to and during the COVID-19 pandemic (2015-2021)

2021 ◽  
Author(s):  
Juliana de Oliveira Costa ◽  
Malcolm B. Gilles ◽  
Andrea L Schaffer ◽  
David Peiris ◽  
Helga Zoega ◽  
...  
Keyword(s):  
Age Groups ◽  
Female Adolescents ◽  
First Year ◽  
Age Group ◽  
Depression And Anxiety ◽  
Differential Impact ◽  
Young Females ◽  
Health Burden ◽  
Annual Prevalence ◽  
Antidepressant Use

Background: Depression and anxiety affect 4% to 14% of Australians every year; symptoms may have been exacerbated during the COVID-19 pandemic. We examined recent patterns of antidepressant use in Australia in the period 2015 to 2021, which includes the first year of the pandemic. Methods: We used national dispensing claims for people aged ≥10 years to investigate annual trends in prevalent and new antidepressant use (no antidepressants dispensed in the year prior). We conducted stratified analyses by sex, age group and antidepressant class. We report outcomes from 2015 to 2019 and used time series analysis to quantify changes during the first year of the COVID-19 pandemic (March 2020 to February 2021). Results: In 2019 the annual prevalence of antidepressant use was 170.4 per 1,000 women and 101.8 per 1,000 men, an increase of 7.0% and 9.2% from 2015, respectively. New antidepressant use also increased for both sexes (3.0% for women and 4.9% for men) and across most age groups, particularly among adolescents (aged 10-17 years; 46%-57%). During the first year of the COVID-19 pandemic, we observed higher than expected prevalent use (+2.2%, 95%CI 0.3%, 4.2%) among females, corresponding to a predicted excess of 45,217 (95%CI 5,819, 84,614) females dispensed antidepressants. The largest increases during the first year of the pandemic occurred among female adolescents for both prevalent (+11.7%, 95%CI 4.1%, 20.5%) and new antidepressant use (+15.6%, 95%CI 8.5%, 23.7%). Conclusion: Antidepressant use continues to increase in Australia overall and especially among young people. We found a differential impact of the COVID-19 pandemic in treated depression and anxiety, greater among females than males, and greater among young females than other age groups, suggesting an increased mental health burden in populations already on a trajectory of increased use of antidepressants prior to the pandemic. Reasons for these differences require further investigation.

CLINICAL AND MORPHOLOGICAL CHARACTERISTICS OF H. PYLORI-ASSOCIATED GASTRODUODENAL ZONE DISEASES: AGE-RELATED ASPECTS

2021 ◽  
pp. 89-99
Author(s):  
E.M. Shul'gina ◽  
Zh.G. Simonova
Keyword(s):  
Helicobacter Pylori ◽  
Clinical Picture ◽  
Average Length ◽  
Eradication Therapy ◽  
Young Patients ◽  
Morphological Characteristics ◽  
Prospective Clinical Study ◽  
Age Related ◽  
H Pylori ◽  
Gastroduodenal Zone

The aim of the paper is to study the clinical and morphological characteristics of H. pylori-associated gastroduodenal zone diseases, depending on patients’ age. Materials and Methods. Three groups of patients of various ages with H. pylori-associated gastroduodenal zone diseases were formed in the course of a prospective clinical study. We studied the clinical picture, and morphological characteristics of the gastroduodenal zone before and after eradication therapy. Average length of the observation period was 172 days. All patients underwent esophagogastroduodenoscopy with biopsy. Results. Severe dyspeptic disorders were diagnosed in all young patients belonging to group 1 (100 %). The dyspeptic index corresponded to a high degree of severity. Morphological changes in the gastric mucosa were more significant in patients with a less pronounced clinical picture (Groups 2 and 3). In group 3, atrophic transformations of the gastric corpus were found in 30.5 %, atrophic transformations of the pylorus – in 11 %, and intestinal metaplasia – in 2.8 % of patients. Unlike young and middle-aged patients with pronounced dyspeptic syndrome, elderly patients were characterized by a low-symptom clinical picture, which was accompanied by morphological gastroduodenal zone transformations with the possible progression. Conclusions. Effective eradication therapy contributes to clinical, endoscopic and morphological remission of the gastroduodenal zone and prevents the progression of the inflammatory cascade. Key words: Helicobacter pylori, gastroduodenal diseases, eradication therapy, age characteristics. Цель исследования – изучить клинико-морфологические особенности H. рylori-ассоциированных заболеваний гастродуоденальной зоны в зависимости от возраста пациентов. Материалы и методы. В процессе проспективного клинического исследования были сформированы три группы пациентов разного возраста, имеющих H. pylori-ассоциированные заболевания гастродуоденальной зоны. Изучали клиническую картину, морфологические особенности гастродуоденальной зоны до и после эрадикационной терапии. Период наблюдения больных составил в среднем 172 дня. Всем пациентам выполнялась ззофагогастродуоденоскопия с биопсией. Результаты. У 100 % пациентов молодого возраста (I группа) установлены выраженные диспепсические расстройства. Диспепсический индекс соответствовал высокой степени тяжести. Для пациентов II и Ш групп при менее выраженной клинической картине морфологические изменения слизистой оболочки желудка оказались более существенны. В старшей группе (Ш группа) атрофические преобразования тела желудка выявлены у 30,5 % пациентов, привратника желудка – у 11 %, кишечная метаплазия – у 2,8 %. В отличие от пациентов молодого и среднего возраста, имеющих выраженный диспепсический синдром, для пациентов пожилого возраста характерна малосимптомная клиническая картина, которая сопровождалась морфологическими преобразованиями гастродуоденальной зоны с возможностью прогрессирования. Выводы. Эффективная эрадикационная терапия способствует достижению клинико-эндоскопической и морфологической ремиссии состояния гастродуоденальной зоны и создает условия для предотвращения прогрессирования воспалительного каскада. Ключевые слова: Helicobacter pylori, заболевания гастродуоденальной зоны, эрадикационная терапия, возрастные особенности.

scholarly journals The Costs Associated with Antidepressant Use in Depression and Anxiety in Community-Living Older Adults

2013 ◽  
Vol 58 (4) ◽  
pp. 201-209 ◽  
Author(s):  
Helen-Maria Vasiliadis ◽  
Eric Latimer ◽  
Pierre-Alexandre Dionne ◽  
Michel Préville
Keyword(s):  
Older Adults ◽  
Community Living ◽  
Depression And Anxiety ◽  
Antidepressant Use

Acromegaly and Depression

1981 ◽  
Vol 139 (5) ◽  
pp. 467-468 ◽  
Author(s):  
A. Margo
Keyword(s):  
Clinical Picture ◽  
Depression And Anxiety ◽  
Psychiatric Complications

There is only a small literature on the psychiatric complications of acromegaly. Manfred Bleuler (1954) reported an acromegalic man who had blunted affect and apathy and suggested that this clinical picture represented a special variation of the endocrine psychosyndrome. Avery (1973) reported a further case of depression and anxiety in association with the illness. There are relevant reviews by Michael and Gibbons (1963), Beumont (1972), Labhart (1974) and Lishman (1978).

Oxidative DNA damage is associated with antidepressant use, not depression or anxiety disorders

2016 ◽  
Vol 33 (S1) ◽  
pp. s219-s219
Author(s):  
C. Black ◽  
M. Bot ◽  
P. Scheffer ◽  
B. Penninx
Keyword(s):  
Oxidative Stress ◽  
Dna Damage ◽  
Anxiety Disorder ◽  
Anxiety Disorders ◽  
Large Scale ◽  
Oxidative Dna Damage ◽  
Antioxidant Properties ◽  
Depression And Anxiety ◽  
Antidepressant Use ◽  
Competing Interest

IntroductionOxidative stress has been implicated in the pathophysiology of depression and anxiety disorders and may be influenced by antidepressant use.ObjectivesThis study investigated the association of oxidative stress, measured by plasma levels of F2-isoprostanes and 8-hydroxy-2′-deoxyguanosine (8-OHdG), reflecting oxidative lipid and DNA damage respectively, with major depressive disorder (MDD), generalized anxiety disorder, social phobia, panic disorder, agoraphobia and antidepressant use in a large cohort.MethodsData was derived from the Netherlands Study of Depression and Anxiety including patients with current (n = 1641) or remitted (n = 610) MDD and/or anxiety disorder(s) (of which n = 709 antidepressant users) and 633 controls. Diagnoses were established with the Composite Interview Diagnostic Instrument. Plasma 8-OHdG and F2-isoprostanes were measured using UHPLC-MS/MS. ANCOVA was performed adjusting for sampling, sociodemographic, health and lifestyle variables.ResultsF2-isoprostanes did not differ between controls and patients, or by antidepressant use. Patients (current or remitted) using antidepressants had lower 8-OHdG (adjusted mean 38.3 pmol/L) compared to patients (current or remitted) without antidepressants (44.7 pmol/L) and controls (44.9 pmol/L, P < 0.001; Cohen's d 0.26). Findings for 8-OHdG were similar over all disorders and all antidepressant types (SSRIs, TCAs, SNRIs; P < 0.001).ConclusionContrary to previous findings this large-scale study did not find increased oxidative stress measured by F2-isoprostanes or 8-OHdG in MDD or anxiety disorders. 8-OHdG levels were lower in antidepressant users, which suggests antidepressants may have antioxidant properties.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Contributing factors to advanced brain aging in depression and anxiety disorders

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Laura K. M. Han ◽  
Hugo G. Schnack ◽  
Rachel M. Brouwer ◽  
Dick J. Veltman ◽  
Nic J. A. van der Wee ◽  
...  
Keyword(s):  
Anxiety Disorders ◽  
Brain Aging ◽  
Depressive Symptomatology ◽  
Antidepressant Effect ◽  
Future Research ◽  
Depression Symptoms ◽  
Depression And Anxiety ◽  
Biological Stress ◽  
Antidepressant Use ◽  
Brain Age

AbstractDepression and anxiety are common and often comorbid mental health disorders that represent risk factors for aging-related conditions. Brain aging has shown to be more advanced in patients with major depressive disorder (MDD). Here, we extend prior work by investigating multivariate brain aging in patients with MDD, anxiety disorders, or both, and examine which factors contribute to older-appearing brains. Adults aged 18–57 years from the Netherlands Study of Depression and Anxiety underwent structural MRI. A pretrained brain-age prediction model based on >2000 samples from the ENIGMA consortium was applied to obtain brain-predicted age differences (brain PAD, predicted brain age minus chronological age) in 65 controls and 220 patients with current MDD and/or anxiety. Brain-PAD estimates were associated with clinical, somatic, lifestyle, and biological factors. After correcting for antidepressant use, brain PAD was significantly higher in MDD (+2.78 years, Cohen’s d = 0.25, 95% CI −0.10-0.60) and anxiety patients (+2.91 years, Cohen’s d = 0.27, 95% CI −0.08-0.61), compared with controls. There were no significant associations with lifestyle or biological stress systems. A multivariable model indicated unique contributions of higher severity of somatic depression symptoms (b = 4.21 years per unit increase on average sum score) and antidepressant use (−2.53 years) to brain PAD. Advanced brain aging in patients with MDD and anxiety was most strongly associated with somatic depressive symptomatology. We also present clinically relevant evidence for a potential neuroprotective antidepressant effect on the brain-PAD metric that requires follow-up in future research.

Sign in / Sign up

Export Citation Format

Share Document